Wondering if Akeso is still a smart buy after its big run up, or if the best days are already priced in? You are not alone. That is exactly what we are going to unpack. The stock has cooled slightly ...
In 2024, based on the COMPASSION-15 study results, cadonilimab in combination with chemotherapy was approved in China for the first-line treatment of gastric cancer, demonstrating benefit across all ...
Akeso’s bispecific antibody improved overall survival in first-line patients with severe gastric cancer or gastroesophageal junction adenocarcinoma in a phase 3 trial, acing the primary endpoint. The ...
HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific ...
Akeso is adding a pair of late-stage wins to its scorecard in both ankylosing spondylitis and atopic dermatitis while also teeing up a new drug submission for one of the candidates. The Hong ...
HONG KONG, March 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National ...
HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter ...
Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit ...
TipRanks on MSN
Akeso’s innovative drugs included in China’s 2025 NRDL
The latest announcement is out from Akeso, Inc. ( (HK:9926) ).
WKBN Youngstown on MSN
Health care center reaches goal of 1,000 gifts for seniors
The “Gifting for Seniors” drive has been a yearly holiday event since 2020, but this is the most presents the program has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback